Consistency of Current Type 2 Diabetes (T2DM) Treatment Patterns in General Practice Versus the 2013 French Has T2DM Guidelines: A Transversal Study Based on the French IMS LifelinkTM Prospective Diabetes Cohort
Larger, E, Ansolabehere, X, Le Jeunne, P, Grandfils, N, Briand, Y, Gibelin, B
Published in Value in health (01.11.2013)
Published in Value in health (01.11.2013)
Get full text
Journal Article
PO05 Difficultés rencontrées par les médecins généralistes lors de la communication du diagnostic du diabète de type 2 à leurs patients: résultats de l’enquête IntroDia
Penfornis, A, Le Pape, G, Gibelin, B, Salaun-Martin, C, Lee, J, Nagel, F
Published in Diabetes & metabolism (01.03.2015)
Published in Diabetes & metabolism (01.03.2015)
Get full text
Journal Article
P297 L’empagliflozine en addition à l’insuline pendant 78 semaines améliore le contrôle glycémique avec une perte de poids dans le diabète de type 2 (DT2) insuliné
Gibelin, B, Rosenstock, J, Jelaska, A, Kim, G, Broedl, H, Woerle, H
Published in Diabetes & metabolism (01.03.2014)
Published in Diabetes & metabolism (01.03.2014)
Get full text
Journal Article
P291 Sécuriré cardio-vasculaire de la linagliptine chez des patients diabétiques de type 2 (DT2) : une analyse groupée rigoureuse des évènements susceptibles d’être intervenus au cours d’études de phase III
Gibelin, B, Johansen, O, Neubacher, D, Seck, T, Patel, S, Woerle, H
Published in Diabetes & metabolism (01.03.2014)
Published in Diabetes & metabolism (01.03.2014)
Get full text
Journal Article
P311 Empagliflozine chez des patients diabétiques de type 2 (DT2) avec insuffisance rénale (IR)
Gibelin, B, Barnett, A, Mithal, A, Manassie, J, Jones, R, Rattunde, H, Woerle, H, Broedl, U
Published in Diabetes & metabolism (01.03.2014)
Published in Diabetes & metabolism (01.03.2014)
Get full text
Journal Article
P295 L’empagliflozine améliore les paramètres glycémiques et les facteurs de risques cardio-vasculaires de patients diabétiques (type 2, DT2) : données groupées de quatre études pivots (phase III)
Gibelin, B, Hach, T, Gerich, J, Salsali, A, Kim, G, Hantel, S, Woerle, H, Broedl, U
Published in Diabetes & metabolism (01.03.2014)
Published in Diabetes & metabolism (01.03.2014)
Get full text
Journal Article
P296 L’empagliflozine (EMPA) augmente les infections génitales (IG) mais non les infections urinaires (IU) dans des données groupées de quatre études pivots de phase III
Gibelin, B, Kim, G, Gerich, J, Salsali, A, Hach, T, Hantel, S, Woerle, H, Broedl, U
Published in Diabetes & metabolism (01.03.2014)
Published in Diabetes & metabolism (01.03.2014)
Get full text
Journal Article
P285 Linagliptine améliore le contrôle glycémique chez les patients atteints de diabète de type 2 indépendamment de la durée du diabète et de l’insulino-résistance
Patel, S, Weber, S, Emser, A, von Eynatten, M, Woerle, H.-J, Gibelin, B
Published in Diabetes & metabolism (01.03.2012)
Published in Diabetes & metabolism (01.03.2012)
Get full text
Journal Article
P284 L’efficacité et la sécurité d’emploi du BI 10773, un nouvel inhibiteur de SGLT-2 (Sodium Glucose cotransporteur de type 2), chez des diabétiques de type 2 insuffisamment contrôlés par la metformine
Rosenstock, J, Jelaska, A, Seman, L, Pinnetti, S, Hantel, S, Woerle, H.J, Gibelin, B
Published in Diabetes & metabolism (01.03.2012)
Published in Diabetes & metabolism (01.03.2012)
Get full text
Journal Article
Comparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers
Strauch, G, Perles, P, Vergult, G, Gabriel, M, Gibelin, B, Cummings, S, Malbecq, W, Malice, M P
Published in European urology (01.01.1994)
Published in European urology (01.01.1994)
Get more information
Journal Article
PDB106 - Consistency of Current Type 2 Diabetes (T2DM) Treatment Patterns in General Practice Versus the 2013 French Has T2DM Guidelines: A Transversal Study Based on the French IMS LifelinkTM Prospective Diabetes Cohort
Larger, E., Ansolabehere, X., Le Jeunne, P., Grandfils, N., Briand, Y., Gibelin, B.
Published in Value in health (01.11.2013)
Published in Value in health (01.11.2013)
Get full text
Journal Article
5 alpha-reductase activity in cultured epithelial and stromal cells from normal and hyperplastic human prostates--effect of finasteride (Proscar), a 5 alpha-reductase inhibitor
Boudon, C, Lobaccaro, J M, Lumbroso, S, Lechevallier, E, Mottet, N, Gibelin, B, Sultan, C
Published in Cellular and molecular biology (Noisy-le-Grand, France) (01.12.1995)
Get more information
Published in Cellular and molecular biology (Noisy-le-Grand, France) (01.12.1995)
Journal Article
Effect of finasteride (Proscar) on the proliferation of cultured epithelial and stromal cells from normal and hyperplastic human prostates
Lobaccaro, J M, Boudon, C, Lechevallier, E, Mottet, N, Rebillard, X, Lumbroso, S, Gibelin, B, Sultan, C
Published in Cellular and molecular biology (Noisy-le-Grand, France) (01.06.1996)
Get more information
Published in Cellular and molecular biology (Noisy-le-Grand, France) (01.06.1996)
Journal Article
Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition
Rhodes, L, Primka, R L, Berman, C, Vergult, G, Gabriel, M, Pierre-Malice, M, Gibelin, B
Published in The Prostate (1993)
Published in The Prostate (1993)
Get more information
Journal Article